| Clinical data | |
|---|---|
| Other names | LY-3471851 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Rezpegaldesleukin is an experimental drug that modulates interleukin-2 [1] [2] [3] and is in development for psoriasis, atopic dermatitis, and alopecia areata. Between 2017 and 2023, it was developed by a partnership of Eli Lilly and Company and Nektar Therapeutics, but the former left the partnership saying the drug lacked efficacy. Nektar disagreed with the interpretation of results, sued its former partner, and is continuing ahead with development. [4] [5] [6]
- ^ Lykhopiy, Valentina; Malviya, Vanshika; Humblet-Baron, Stephanie; Schlenner, Susan M. (23 September 2023). ""IL-2 immunotherapy for targeting regulatory T cells in autoimmunity"". Genes & Immunity. 24 (5): 248–262. doi: 10.1038/s41435-023-00221-y. PMC 10575774. PMID 37741949.
- ^ Huang, Hongpeng (10 October 2023). "Immunotherapeutic approaches for systemic lupus erythematosus: early overview and future potential". Medical Review. doi: 10.1515/mr-2023-0032. ISSN 2749-9642. PMC 10808868. S2CID 263776214.
- ^ Yuan, Yeshuang; Kolios, Antonios G.A.; Liu, Yudong; Zhang, Bo; Li, Hao; Tsokos, George C.; Zhang, Xuan (July 2022). "Therapeutic potential of interleukin-2 in autoimmune diseases". Trends in Molecular Medicine. 28 (7): 596–612. doi: 10.1016/j.molmed.2022.04.010. PMID 35624009.
- ^ Fultinavičiūtė, Urtė (14 September 2023). "Nektar recalculates new efficacy data for rezpegaldesleukin in AD". Clinical Trials Arena. Retrieved 20 November 2023.
- ^ "Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment". Reuters. 7 August 2023. Retrieved 20 November 2023.
- ^ "Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe AD Met Clinical Efficacy Endpoints". Dermatology Times. 13 September 2023. Retrieved 20 November 2023.
| Clinical data | |
|---|---|
| Other names | LY-3471851 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Rezpegaldesleukin is an experimental drug that modulates interleukin-2 [1] [2] [3] and is in development for psoriasis, atopic dermatitis, and alopecia areata. Between 2017 and 2023, it was developed by a partnership of Eli Lilly and Company and Nektar Therapeutics, but the former left the partnership saying the drug lacked efficacy. Nektar disagreed with the interpretation of results, sued its former partner, and is continuing ahead with development. [4] [5] [6]
- ^ Lykhopiy, Valentina; Malviya, Vanshika; Humblet-Baron, Stephanie; Schlenner, Susan M. (23 September 2023). ""IL-2 immunotherapy for targeting regulatory T cells in autoimmunity"". Genes & Immunity. 24 (5): 248–262. doi: 10.1038/s41435-023-00221-y. PMC 10575774. PMID 37741949.
- ^ Huang, Hongpeng (10 October 2023). "Immunotherapeutic approaches for systemic lupus erythematosus: early overview and future potential". Medical Review. doi: 10.1515/mr-2023-0032. ISSN 2749-9642. PMC 10808868. S2CID 263776214.
- ^ Yuan, Yeshuang; Kolios, Antonios G.A.; Liu, Yudong; Zhang, Bo; Li, Hao; Tsokos, George C.; Zhang, Xuan (July 2022). "Therapeutic potential of interleukin-2 in autoimmune diseases". Trends in Molecular Medicine. 28 (7): 596–612. doi: 10.1016/j.molmed.2022.04.010. PMID 35624009.
- ^ Fultinavičiūtė, Urtė (14 September 2023). "Nektar recalculates new efficacy data for rezpegaldesleukin in AD". Clinical Trials Arena. Retrieved 20 November 2023.
- ^ "Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment". Reuters. 7 August 2023. Retrieved 20 November 2023.
- ^ "Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe AD Met Clinical Efficacy Endpoints". Dermatology Times. 13 September 2023. Retrieved 20 November 2023.